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Covalent dimerization of the adrenocorticotropin fragment ACTH,,_, increases its antagonistic potency 
on the ACTH-induced steroidogenesis n isolated bovine fasciculata/reticularis cells by 3 orders of magni- 
tude when the C-termini are linked via a 10 A long spacer. This strong potentiation, probably mediated 
by cross-linking of tht receptors, was shown to be dependent on the point of attachment of the monomeric 
fragment to the spacer, thus providing information about the position of the binding site in the hormonal 
segment and about the distance of the receptors on the cell surface. 
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1. INTRODUCTION 
ACTHr r -24 has been demonstrated to be a com- 
petitive antagonist of ACTHI-39 and of 
ACTHI_ro for the stimulation of steroidogenesis 
in isolated adrenal cells [l]. This observation fits 
the current theory of the organization of the infor- 
mation in the ACTH molecule according to which 
the sequence 11-24 is not involved in activation 
but provides affinity to the receptor [2]. Covalent 
dimeric conjugates of peptide hormones [3,4] and 
of non-peptide drugs [5,6] have been suggested to 
act as bivalent ligands and to be able to cross-link 
receptors. No such conjugates have been reported 
in the ACTH field so far. In addition, there is a 
need for potent ACTH antagonists, the potency of 
the natural [7] and synthetic [f&9,10] inhibitors 
known to date being generally low. 
The purpose of our work was therefore to 
prepare bivalent conjugates of ACTH fragments, 
starting with antagonistic moieties, and paying 
special attention to the point of attachment of the 
peptide and to the structure of the spacer. We have 
synthesized the two compounds shown in fig.1, in 
which two ACTHr I -24 fragments are covalently at- 
tached through either their terminal carboxy or ter- 
minal amino groups. The two functional groups of 
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Fig.1. Chemical structure of the dimeric conjugates of 
ACTHll_24 obtained with the spacers iV-acetylglutamic 
acid (1) and lysine amide (2), respectively. 
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acetylglutamic acid and of lysine amide, respec- 
tively, were chosen for the covalent binding of the 
hormonal fragments. In this way, the spacer also 
was an amino acid attached and protected 
throughout via amide bonds. Measuring 
steroidogenesis n the isolated adrenal cell system, 
we were able to show that compounds 1 and 2 ex- 
hibited the potentiating effect expected for such 
bivalent conjugates, and that the effect was very 
sensitive to the structure of the dimer. 
2. MATERIALS AND METHODS 
Compounds 1 and 2 (fig.1) were synthesized 
from the protected fragment H-Lys(Boc)-Pro-Val- 
Gly-Lys(Boc)-Lys(Boc)-Arg-Arg-Pro-Val-Lys- 
(Boc)-Val-Tyr-Pro-OH,2HCl industrially prepared 
and kindly provided by CIBA-Geigy, Basel, and 
from the derivatized spacers AC-Glu-OBzl and H- 
Lys(Fmoc)-NH2 (prepared in our laboratory), us- 
ing the methods of classical peptide synthesis in 
solution [ 111. The products were isolated as pure 
hydrochlorides after cleavage of the protecting 
groups under acidic conditions and gel filtration 
on Sephadex L60 in methanol. Details of the syn- 
thesis will be published elsewhere [ 121. The ratio of 
glutamic acid in conjugate 1 and of lysine in 2, to 
the other amino acids after total hydrolysis and 
amino-acid analysis, was a convenient means to 
prove covalent dimerization. 
Isolated bovine fasciculata/reticularis cells were 
prepared by collagenase dispersion by a modifica- 
tion of the method of Haning et al. [13] as des- 
cribed elsewhere [141. One ml aliquots of the cell 
suspension (300000 cells) were incubated for 
60 min at 37°C under 95% 02/5% CO2, in the 
presence of various concentrations of ACTHi- 
and/or the synthetic ACTHii-24 monomer and 
dimers. At the end of the incubation period, the 
cells were sedimented by centrifugation, and the 
corticosterone (B) content determined by radioim- 
munoassay, either directly or after CC4 extrac- 
tion, using a rabbit antiserum raised against 
corticosterone-21-hemisuccinate-BSA conjugate 
and dextran charcoal separation. No difference in 
B levels was observed, whether the media had been 
assayed directly or extracted with CCld. Cross- 
reaction with cortisol was less than 1% and this 
steroid was found to be produced in equivalent 
amounts to corticosterone. 
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3. RESULTS 
The dimeric conjugates 1 and 2 failed to activate 
B production at any dose up to 10e5 M. The 
monomer ACTHii-24 was inactive at doses lower 
than 10e6 M, showing however a light enhance- 
ment of B over the basal value 13.0 +- 2.5 to 15.6 
+ 2.5 ng/ml per h (not shown). 
In the presence of a fixed amount (lo-” M) of 
the agonist ACTHi-24, the response was not af- 
fected by ACTHii-2s up to 2 x 10u5 M, while the 
two dimers 1 and 2 markedly depressed or com- 
pletely suppressed B production, respectively 
(fig.2). 
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Fig.2. Effects of ACTHI,_24 (o), of dimer 1 (A) and 2 
(m) on corticosterone production induced by ACTHi- 
at 10-r’ M. Each point is the mean of triplicate 
determinations from two separate experiments. 
kc 
8 0' 10~" 10" lo-" lo-'O 10-q 1o-8 10' 
ACTH,.2L CONCENTRATION (M) 
Fig.3. Log dose response curves of ACTHr-24 induced 
B production in the absence of antagonist (0) or in the 
presence of lo-’ M ACTHrr-24 (0) or of dimer 1 (A) or 
2 (m). Each point is the mean (k SE) of triplicate 
determinations from two separate experiments. 
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The log dose response curve of ACTH1_z4 for B 
production at constant inhibitor concentration 
(lo-’ M) was shifted to the right by the two dimers 
while the monomer ACTHII-24 had little effect. 
From computer analysis the dose to induce l/2 
&,,,,wasfoundtobe5.3(~3.1)~10-13Mforthe 
agonist alone or 3.92 ( f 1.08) x 10-r’ M and 2.14 
(k 0.92) x 10m9 M in the presence of conjugate 1 
or 2, respectively. 
4. DISCUSSION 
Due to the bivalent structure of the new 
derivatives, an evaluation of the inhibitory cons- 
tant according to the classical kinetic model for 
competitive inhibition is no longer possible. 
However, the 75 and 4050-fold increase of the 
EDso for ACTHi- at lO-5 M of conjugate 1 and 
2, respectively, compared to the hardly measurable 
effect of the monomer ACTHlr-24 under the same 
conditions, represents a most significant effect of 
covalent dimerization. A direct visualization of the 
molecular processes involved at the cellular surface 
is impossible without the effector molecules being 
radioactively or fluorescently labelled. However, it 
is reasonable to admit that potentiation is primari- 
ly due to cross-linking of the receptor sites. The en- 
suing potency increase considerably greater than 
the statistical factor of two can tentatively be ex- 
plained by a more favorable entropy change for 
the bridging by a single bivalent ligand than for the 
univalent binding of two bivalent ligands [6]. 
Cross-linking generally induces a microaggrega- 
tion of the receptors and the latter process is 
thought to be necessary for the generation of an 
immediate biological response, also when 
monovalent agonists are applied [ 151. When using 
antagonists, microaggregation can be promoted by 
complexes of the antagonist with bivalent an- 
tibodies, leading in some instances to the conver- 
sion of the antagonist to an agonist [4,16]. 
However, with our inhibitors no such conversion 
took place and it was the antagonistic effect which 
was amplified. Our dimeric conjugates, in contrast 
to the monomer, might indeed cause an aggrega- 
tion of the receptor sites. However, the resulting 
clusters would not be functional. Moreover, they 
would prevent further receptor stimulation either 
through alteration of the binding sites or by block- 
ing the access to them. Support for the postulated 
mechanism might be gained from the synthesis (in 
progress) and testing of bivalent conjugates of the 
agonist ACTHr-24. 
The difference in potency between the two con- 
jugates 1 and 2 is also very informative. The 
stronger effect observed for conjugate 2 is in- 
dicative of a better interaction with the receptor 
sites and therefore of stronger binding elements 
near the N-terminal region of the monomer. Tak- 
ing in account an approximate length of 7-10 A 
for the spacer and of 22 A [17] for the monomer, 
a mean distance of 25-35 A between two receptors 
can be estimated. Variation of the spacer length 
(not performed here) may help to settle these 
values more precisely and to optimize the an- 
tagonistic potency. Finally, it seems reasonable to 
expect that starting with N-terminal elongated 
monomers of ACTHi l-24 [ 181, even stronger 
ACTH inhibitors should be obtained by the same 
method of covalent dimerization. 
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